Sign in or create an account to add this stock to your watchlist.
About Bellerophon Therapeutics (NASDAQ:BLPH)
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. Its products are also used for other pulmonary hypertension conditions. The company was founded in 2009 and is headquartered in Warren, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BLPH
CUSIPN/A
Phone908-574-4770
Debt
Debt-to-Equity RatioN/A
Current Ratio4.14
Quick Ratio4.14
Price-To-Earnings
Trailing P/E Ratio-2.52
Forward P/E Ratio-9.87
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.04 per share
Price / Book56.75
Profitability
EPS (Most Recent Fiscal Year)($0.90)
Net Income$-54,810,000.00
Net MarginsN/A
Return on Equity-567.03%
Return on Assets-60.54%
Miscellaneous
Employees20
Outstanding Shares57,470,000
Bellerophon Therapeutics (NASDAQ:BLPH) Frequently Asked Questions
What is Bellerophon Therapeutics' stock symbol?
Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."
How were Bellerophon Therapeutics' earnings last quarter?
Bellerophon Therapeutics Inc (NASDAQ:BLPH) announced its quarterly earnings data on Thursday, March, 15th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.24). View Bellerophon Therapeutics' Earnings History.
When is Bellerophon Therapeutics' next earnings date?
What price target have analysts set for BLPH?
1 brokers have issued 12 month price targets for Bellerophon Therapeutics' shares. Their predictions range from $5.00 to $5.00. On average, they anticipate Bellerophon Therapeutics' share price to reach $5.00 in the next year. View Analyst Ratings for Bellerophon Therapeutics.
Who are some of Bellerophon Therapeutics' key competitors?
Some companies that are related to Bellerophon Therapeutics include Evelo Biosciences (EVLO), Cara Therapeutics (CARA), Mersana Therapeutics (MRSN), Achillion Pharmaceuticals (ACHN), Aurinia Pharmaceuticals (AUPH), Obseva (OBSV), Zealand Pharma (ZEAL), Clementia Pharmaceuticals (CMTA), Cytokinetics (CYTK), Concert Pharmaceuticals (CNCE), Zymeworks (ZYME), ProMetic Life Sciences (PFSCF), GTX (GTXI), Innate Pharma (IPHYF) and Merus (MRUS).
Who are Bellerophon Therapeutics' key executives?
Bellerophon Therapeutics' management team includes the folowing people:
- Mr. Fabian Tenenbaum, CEO & Director (Age 44)
- Dr. Deborah A. Quinn, Chief Medical Officer (Age 64)
- Mr. Peter Fernandes, Chief Regulatory & Safety Officer (Age 63)
- Assaf Korner, CFO & Sec. (Age 40)
- Ms. Amy Edmonds, VP of Clinical Operations & Admin. (Age 46)
When did Bellerophon Therapeutics IPO?
(BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.
Has Bellerophon Therapeutics been receiving favorable news coverage?
News stories about BLPH stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bellerophon Therapeutics earned a daily sentiment score of 0.05 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 47.17 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Bellerophon Therapeutics' major shareholders?
Which institutional investors are buying Bellerophon Therapeutics stock?
How do I buy shares of Bellerophon Therapeutics?
Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bellerophon Therapeutics' stock price today?
One share of BLPH stock can currently be purchased for approximately $2.27.
How big of a company is Bellerophon Therapeutics?
Bellerophon Therapeutics has a market capitalization of $129.94 million. The biotechnology company earns $-54,810,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Bellerophon Therapeutics employs 20 workers across the globe.
How can I contact Bellerophon Therapeutics?
Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at 908-574-4770 or via email at [email protected]
MarketBeat Community Rating for Bellerophon Therapeutics (BLPH)
MarketBeat's community ratings are surveys of what our community members think about Bellerophon Therapeutics and other stocks. Vote "Outperform" if you believe BLPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
Bellerophon Therapeutics (NASDAQ:BLPH) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Bellerophon Therapeutics in the last 12 months. Their average twelve-month price target is $5.00, suggesting that the stock has a possible upside of 120.26%. The high price target for BLPH is $5.00 and the low price target for BLPH is $5.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $5.00 | $5.00 | $4.75 | $4.75 |
| Price Target Upside: | 120.26% upside | 163.16% upside | 302.54% upside | 302.54% upside |
Bellerophon Therapeutics (NASDAQ:BLPH) Consensus Price Target History
Bellerophon Therapeutics (NASDAQ:BLPH) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Bellerophon Therapeutics (NASDAQ:BLPH) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Bellerophon Therapeutics (NASDAQ BLPH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 57.80%
Institutional Ownership Percentage: 58.10%
Bellerophon Therapeutics (NASDAQ BLPH) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/9/2016 | Jens Luehring | Director | Buy | 20,000 | $0.56 | $11,200.00 | 39,860 |  |
| 5/17/2016 | Jonathan M Peacock | CEO | Buy | 5,000 | $1.37 | $6,850.00 | 222,702 | |
| 12/16/2015 | Jonathan M. Peacock | CEO | Buy | 20,300 | $2.75 | $55,825.00 | 51,727 | |
| 8/19/2015 | Jonathan M Peacock | CEO | Buy | 5,000 | $5.48 | $27,400.00 | 31,427 | |
| 5/20/2015 | Jonathan M Peacock | CEO | Buy | 5,560 | $8.69 | $48,316.40 | | |
| 2/19/2015 | Daniel Tasse | Director | Buy | 25,000 | $12.00 | $300,000.00 | | |
| 2/19/2015 | Jonathan M Peacock | CEO | Buy | 20,800 | $12.00 | $249,600.00 | | |
| 2/19/2015 | Linde North America, Inc. | Major Shareholder | Buy | 358,916 | $12.00 | $4,306,992.00 | | |
| 2/19/2015 | Manesh Naidu | Insider | Buy | 1,500 | $12.00 | $18,000.00 | | |
(Data available from 1/1/2013 forward)
Bellerophon Therapeutics (NASDAQ BLPH) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Bellerophon Therapeutics (BLPH) Expected to Announce Earnings of -$0.14 Per Share
www.americanbankingnews.com - May 18 at 10:31 AM |
 | Bellerophon to Present Positive Results from Phase 2 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease at the American Thoracic Society 114th International Conference
finance.yahoo.com - May 16 at 5:50 PM |
| HC Wainwright Reiterates "Buy" Rating for Bellerophon Therapeutics (BLPH)
www.americanbankingnews.com - May 11 at 5:49 PM |
| Bellerophon Provides Business Update and Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 10 at 6:04 PM |
 | Bellerophon Therapeutics (BLPH) Reports Agreement with FDA on Study Design of Phase 2b Trial of INOpulse for ...
www.streetinsider.com - May 9 at 8:13 AM |
 | FDA signs off on design of Phase 2b study of INOpulse in PH-COPD
seekingalpha.com - May 8 at 5:46 PM |
| Bellerophon Reaches Agreement with FDA on Study Design of Phase 2b Trial of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease
finance.yahoo.com - May 8 at 5:46 PM |
| Bellerophon Therapeutics (BLPH) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - May 7 at 3:46 AM |
| Zacks: Analysts Expect Bellerophon Therapeutics (BLPH) Will Announce Earnings of -$0.14 Per Share
www.americanbankingnews.com - April 30 at 9:16 PM |
| 3 Biotech Stocks That Will Thrive Amid Market Instability
finance.yahoo.com - April 27 at 8:25 AM |
| Zacks: Analysts Anticipate Bellerophon Therapeutics (BLPH) Will Announce Earnings of -$0.14 Per Share
www.americanbankingnews.com - April 13 at 9:17 PM |
| Bellerophon Therapeutics (BLPH) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - April 12 at 10:18 PM |
| Bellerophon Therapeutics (BLPH) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 11 at 5:38 PM |
| ValuEngine Upgrades Bellerophon Therapeutics (BLPH) to Hold
www.americanbankingnews.com - April 4 at 12:02 AM |
| Bellerophon Therapeutics to Provide Corporate Update at H.C. Wainwright Annual Global Life Sciences Conference
finance.yahoo.com - April 3 at 5:39 PM |
| Contrasting AEterna Zentaris (AEZS) and Bellerophon Therapeutics (BLPH)
www.americanbankingnews.com - March 31 at 9:05 AM |
| Form 3 Bellerophon Therapeutics For: Mar 22 Filed by: BENNETT MATTHEW
www.streetinsider.com - March 30 at 5:36 PM |
| Blog Exposure - Intercept Pharma to Present Multiple New Ocaliva Data at International Liver Congress 2018
finance.yahoo.com - March 27 at 8:20 AM |
| Will Bellerophon Therapeutics (BLPH) Continue to Surge Higher?
finance.yahoo.com - March 23 at 5:48 PM |
| Bellerophon Therapeutics (BLPH) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 22 at 6:56 PM |
| Bellerophon Therapeutics' (BLPH) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - March 21 at 1:02 PM |
 | Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 16 at 8:13 AM |
| Bellerophon Therapeutics (BLPH) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - March 16 at 12:48 AM |
| Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
finance.yahoo.com - March 15 at 6:18 PM |
| Bellerophon Therapeutics Inc (BLPH) Expected to Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - March 10 at 5:22 PM |
| -$0.24 EPS Expected for Bellerophon Therapeutics Inc (BLPH) This Quarter
www.americanbankingnews.com - February 21 at 11:14 PM |
| Bellerophon Therapeutics (BLPH) Reports Enrollment Exceeds 100 Patients in Phase 3 INOvation-1 Study Evaluating ... - StreetInsider.com
www.streetinsider.com - January 30 at 3:40 PM |
 | ARDM Chokes, ABEO On Track, MASI Gets FDA Nod, ALBO Up 50% YTD - Nasdaq
www.nasdaq.com - January 30 at 3:40 PM |
| Bellerophon Therapeutics Announces Enrollment Exceeds 100 Patients in Phase 3 INOvation-1 Study Evaluating INOpulse® for Treatment of Pulmonary Arterial Hypertension
finance.yahoo.com - January 29 at 9:10 AM |
| Brokerages Anticipate Bellerophon Therapeutics Inc (BLPH) to Announce -$0.24 Earnings Per Share
www.americanbankingnews.com - January 19 at 1:06 AM |
| Brokerages Set $5.00 Price Target for Bellerophon Therapeutics Inc (BLPH)
www.americanbankingnews.com - January 12 at 9:32 AM |
| Bellerophon Therapeutics (BLPH) Reports First Patient Enrolled in Phase 2b Study Evaluating INOpulse for Treatment ... - StreetInsider.com
www.streetinsider.com - January 3 at 4:51 PM |
| Bellerophon Announces First Patient Enrolled in Phase 2b Study Evaluating INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
finance.yahoo.com - January 3 at 9:25 AM |
| Zacks: Brokerages Anticipate Bellerophon Therapeutics Inc (BLPH) Will Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - January 2 at 7:34 AM |
| Analyzing Bellerophon Therapeutics (BLPH) and Its Rivals
www.americanbankingnews.com - December 29 at 11:30 PM |
| Head to Head Analysis: Bellerophon Therapeutics (BLPH) vs. Dynavax Technologies (DVAX)
www.americanbankingnews.com - December 29 at 3:24 PM |
| Critical Contrast: Bellerophon Therapeutics (BLPH) vs. The Competition
www.americanbankingnews.com - December 27 at 10:00 AM |
| Zacks: Bellerophon Therapeutics Inc (BLPH) Given $5.00 Consensus Target Price by Brokerages
www.americanbankingnews.com - December 26 at 1:10 AM |
| Bellerophon Therapeutics, Inc. (BLPH) Sees Large Decrease in Short Interest
www.americanbankingnews.com - December 16 at 2:08 AM |
| Zacks: Bellerophon Therapeutics, Inc. (BLPH) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - December 10 at 7:32 AM |
| Bellerophon Therapeutics (BLPH) & Its Competitors Financial Analysis
www.americanbankingnews.com - December 6 at 3:08 PM |
| Analysts Anticipate Bellerophon Therapeutics, Inc. (BLPH) to Announce ($0.24) Earnings Per Share
www.americanbankingnews.com - December 3 at 9:46 PM |
| Bellerophon Appoints Ted Wang, Ph.D., of Puissance Capital Management, to its Board of Directors
finance.yahoo.com - December 1 at 5:25 PM |
| Zacks: Analysts Anticipate Bellerophon Therapeutics, Inc. (BLPH) Will Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - November 28 at 7:56 AM |
| Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 8 at 5:32 AM |
| Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 7:28 PM |
| Bellerophon Therapeutics posts 3Q loss
finance.yahoo.com - November 7 at 7:28 PM |
| Bellerophon Therapeutics, Inc. (BLPH) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 8:50 AM |
 | BRIEF-Bellerophon Therapeutics says selling stockholders may offer, resell up to 38.9 mln shares - SEC filing
www.reuters.com - October 24 at 11:42 PM |
| Bellerophon Announces $23 Million Private Placement
finance.yahoo.com - October 2 at 12:59 PM |
Bellerophon Therapeutics (NASDAQ:BLPH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Bellerophon Therapeutics (NASDAQ:BLPH) Income Statement, Balance Sheet and Cash Flow Statement
Bellerophon Therapeutics (NASDAQ BLPH) Stock Chart for Saturday, May, 26, 2018
Loading chart…
